The FDA-approved neuroleptic agent Pimozide was identified in a high-throughput screen as an inhibitor of STAT5 phosphorylation and an inducer of apoptosis in CML cell lines [149]. The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.